Nanexa AB (FRA:40M) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:40M Nanexa AB FRA:40M
53 GF Score
Price €0.31
GF Value €0.17
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Nanexa AB Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:40M
53GF Score
Nanexa AB FRA:40M
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nanexa AB (FRA:40M) Overvalued in 2026?

Based on GuruFocus' analysis, Nanexa AB stock appears to be overvalued. The current stock price of €0.31 is trading 83.5% above its estimated GF Value™ of €0.17. GuruFocus considers Nanexa AB to be Significantly Overvalued.

Key valuation signals for FRA:40M:

  • Short Ratio:
  • GF Value™: €0.17 vs. price of €0.31 (83.5% above fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the FRA:40M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nanexa AB Business Description

Other Exchanges NANEXA:Sweden
Address Virdings Alle 32B, Uppsala, SWE, 75450
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries, while it also has its presence in Europe (excluding the Nordic countries), North America, and Asia.
53GF Score

Get the complete analysis for FRA:40M

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.31
Price
€0.17
GF Value